Tecentriq Indication for Previously Untreated Advanced Bladd

Tecentriq Indication for Previously Untreated Advanced Bladder Cancer Withdrawn

Genentech has voluntarily withdrawn the US indication for Tecentriq (atezolizumab) for previously untreated urothelial carcinoma.

Related Keywords

Levi Garraway , Approval Program , Genentech , Drug Administration , Global Product Development At Genentech , Global Product Development ,